2019 年結直腸癌肝轉移診療指南最新解讀_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

常文舉 ^1,2,3 , 任黎 ^1,2,3 ,  許劍民 ^1,2,3

1. ;
2. ;
3. ;

Corresponding?author：

許劍民, Email: xujmin@aliyun.com

Keywords：

DOI：

10.7507/1007-9424.201905108

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 常文舉, 任黎, 許劍民. 2019 年結直腸癌肝轉移診療指南最新解讀. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(8): 907-911. doi: 10.7507/1007-9424.201905108 Copy

1.	Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol, 2010, 21 Suppl 5: v93-v97.
2.	中華醫學會外科分會胃腸外科學組, 中華醫學會外科分會結直腸外科學組, 中國抗癌協會大腸癌專業委員會, 等. 中國結直腸癌肝轉移診斷和綜合治療指南(v2018). 中華結直腸疾病電子雜志, 2018, 7(4): 302-314.
3.	中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會(CSCO)結直腸癌診療指南(2019.V1). 北京: 人民衛生出版社, 2019: 1-139.
4.	Guidelines N. Recent updates to NCCN Clinical Practice Guidelines in Oncology-Colon Cancer Version 2.2019 and Rectal Cancer Version 2.2019. https://www.nccn.org/professionals/physician_gls/recently_updated.aspx.
5.	Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol, 2016, 27(8): 1386-1422.
6.	Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol, 2013, 31(16): 1931-1938.
7.	Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol, 2014, 15(10): 1065-1075.
8.	Van Cutsem E, K?hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009, 360(14): 1408-1417.
9.	De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol, 2010, 11(8): 753-762.
10.	Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013, 369(11): 1023-1034.
11.	Kopetz S, McDonough SL, Lenz HJ, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol, 2017, 35(15 Suppl): 3505.
12.	Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol, 2015, 33(34): 4023-4031.
13.	van Cutsem E, Cuyle PJ, Huijberts S. BEACON CRC study safety lead-in (SLI) in patients with BRAF^V600E metastatic colorectal cancer (mCRC): efficacy and tumor markers. J Clin Oncol, 2018, 36(4 Suppl): 627.
14.	Benson AB 3^rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(3): 370-398.
15.	Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol, 2019, 30(2): 171-210.
16.	Zheng P, Ren L, Feng Q, et al. Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. Am J Cancer Res, 2018, 8(11): 2337-2345.
17.	Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol, 2018, 19(5): 660-671.
18.	Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 303-312.
19.	Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2015, 16(6): 619-629.
20.	Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA, 2018, 319(24): 2486-2496.

1. Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol, 2010, 21 Suppl 5: v93-v97.
2. 中華醫學會外科分會胃腸外科學組, 中華醫學會外科分會結直腸外科學組, 中國抗癌協會大腸癌專業委員會, 等. 中國結直腸癌肝轉移診斷和綜合治療指南(v2018). 中華結直腸疾病電子雜志, 2018, 7(4): 302-314.
3. 中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會(CSCO)結直腸癌診療指南(2019.V1). 北京: 人民衛生出版社, 2019: 1-139.
4. Guidelines N. Recent updates to NCCN Clinical Practice Guidelines in Oncology-Colon Cancer Version 2.2019 and Rectal Cancer Version 2.2019. https://www.nccn.org/professionals/physician_gls/recently_updated.aspx.
5. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol, 2016, 27(8): 1386-1422.
6. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol, 2013, 31(16): 1931-1938.
7. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol, 2014, 15(10): 1065-1075.
8. Van Cutsem E, K?hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009, 360(14): 1408-1417.
9. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol, 2010, 11(8): 753-762.
10. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013, 369(11): 1023-1034.
11. Kopetz S, McDonough SL, Lenz HJ, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol, 2017, 35(15 Suppl): 3505.
12. Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol, 2015, 33(34): 4023-4031.
13. van Cutsem E, Cuyle PJ, Huijberts S. BEACON CRC study safety lead-in (SLI) in patients with BRAF^V600E metastatic colorectal cancer (mCRC): efficacy and tumor markers. J Clin Oncol, 2018, 36(4 Suppl): 627.
14. Benson AB 3^rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(3): 370-398.
15. Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol, 2019, 30(2): 171-210.
16. Zheng P, Ren L, Feng Q, et al. Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. Am J Cancer Res, 2018, 8(11): 2337-2345.
17. Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol, 2018, 19(5): 660-671.
18. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 303-312.
19. Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2015, 16(6): 619-629.
20. Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA, 2018, 319(24): 2486-2496.

Previous Article
直腸癌經肛拖出術的臨床應用
Next Article
腹腔鏡下保留左結腸動脈的直腸癌D3 根治術的爭議與體會

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

2019 年結直腸癌肝轉移診療指南最新解讀

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content